SNY 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上
SNY 近期報酬表現
-0.39%
Sanofi s.a.
2.35%
同產業平均
-0.21%
S&P500
與 SNY 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
GSK | Gsk plc | 3 分 | 5 分 | 4 分 | 2 分 | 5 分 | |
NVS | Novartis ag | 2 分 | 4 分 | 5 分 | 2 分 | 5 分 | |
AZN | Astrazeneca plc | 2 分 | 5 分 | 4 分 | 2 分 | 5 分 | |
HLN | Haleon plc | - | 4 分 | 2 分 | 1 分 | 1 分 | |
MRK | Merck & co. , inc. | 3 分 | 4 分 | 4 分 | 3 分 | 5 分 |
- GSK Gsk plc價值 3 分趨勢 5 分波段 4 分籌碼 2 分股利 5 分查看更多
SNY 公司資訊
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi's Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company's products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.